Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Cellink AB: CELLINK awarded patent for temperature-controlled printbed technology.

Read the release

The invention leverages the Peltier effect, resulting in a compact standalone system that is smaller and more robust than systems that use conventional thermoregulation methods.

Now, for research involving temperature-sensitive bioinks like collagen and GelMA, CELLINK's temperature-controlled printbed promises reliable and precise control during the bioprinting process -- which is good news for users bioprinting retinal cells, heart cells, liver cells, cancer models and disease models. The patent complements a full portfolio of bioprinting solutions being developed at CELLINK. 

Bioprinting different biomaterials relies on the ability to control each bioink's individual rate of crosslinking. Conventional printbeds that use circuit boards, PCBs and film heaters pose problems in terms of accuracy and responsiveness, and typically lack a cooling function, according to the patent.

CELLINK set out to develop a different approach. The new printbed enables users to both raise and reduce temperature and the Peltier effect cools down the bioprinter much faster than older methods, offering more control to the user.

The method outlined in the patent makes a large step towards the ideal bioprinter and biomaterial-supporting technology. 

The inventors include Erik Gatenholm and Héctor Martínez, co-founders of CELLINK, as well as Jockum Svanberg and Erik Sternå.

For further information, please contact:

Erik Gatenholm, CEO                                                                                     Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00                                                                         Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                                                    US+1 (857) 332 2138 

Email:eg@cellink.com                                                                                   Email:gd@cellink.com 

About CELLINK

CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team